Skip to main content
TOPICS
Videos
Provider
Payer
Pharma
Consumer
Investor
RESOURCES
Events
Jobs
Learning Center
Webinars
White Papers
REGIONS
ANZ
ASIA
EMEA
Global Edition
MORE
About
Advertise
Contact
Privacy Policy
ANZ
ASIA
EMEA
Global Edition
Illimis Therapeutics
Illimis Therapeutics secures $42M for CNS and immune disease therapies
By
Anthony Vecchione
|
01:07 pm |
July 16, 2025
The funds will be used to increase the development of GAIA-based Alzheimer's disease drugs and widen the pipeline of blockbuster drug candidates.
